Merck secured global rights to a preclinical KRAS G12D (ON) inhibitor-molecular glue program from China’s SciBrunch Therapeutics in a licensing and collaboration deal valued at up to $2.13 billion. The agreement includes $400 million upfront and milestone-based payments tied to development and commercialization across multiple indications. SciBrunch described SPR2015 as an oral candidate with nanomolar antiproliferative activity in KRAS G12D-mutant models and reported strong monotherapy performance across CRC xenograft settings at AACR’s 2026 meeting, including objective response and disease control metrics. The move highlights ongoing re-acceleration in KRAS-targeted strategies where IP and development execution are increasingly being assembled via early global licensing rather than later-stage partnering.